{
  "docId": "019de076-ab6f-74fc-ae2c-88fa7eed31fd",
  "docSlug": "9e6f9592721adb102aeba3d640e068ca",
  "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides",
  "authorId": "immix-biopharma",
  "authorName": "Immix Biopharma",
  "documentKindSlug": "deck",
  "documentKindLabel": "Deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 31,
  "pageCount": 64,
  "prevPage": 30,
  "nextPage": 32,
  "slideType": "market_sizing",
  "function": "size_opportunity",
  "density": "overcrowded",
  "nDataPoints": 8,
  "notes": "Includes a comparative table of clinical outcomes (ORR/CR/sCR) for NXC-201 vs. competitors.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-ab6f-74fc-ae2c-88fa7eed31fd/31",
  "deckHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd",
  "deckJsonHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd.json",
  "deckAnchorHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd#slide-31",
  "components": [
    {
      "bbox": {
        "h": 0.3,
        "w": 0.45,
        "x": 0.02,
        "y": 0.55
      },
      "kind": "chart",
      "text": "Hematologic Cancers Market Size $60B to $120B",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "72c8a6c3-ade8-4199-aa47-e7bf0e09ee64",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.45,
        "x": 0.02,
        "y": 0.28
      },
      "kind": "list",
      "text": "Hematologic cancers market opportunity is $60bn today growing to $120bn in 2028. Multiple Myeloma is 3rd most common blood cancer. AL Amyloidosis has no standard of care.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "64051454-8855-4161-9e87-a561558ec398",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.45,
        "x": 0.53,
        "y": 0.28
      },
      "kind": "list",
      "text": "1. Leveraging market CAR-T experience. 2. Demand exceeds supply. 3. High grade side-effects in current CAR-Ts. 4. Bispecifics/Allogeneic CAR-Ts still in progress.",
      "attrs": null,
      "subkind": "numbered",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "df25d873-8a25-450e-8e40-3840ad0cb054",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.95,
        "x": 0.02,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "Sources: Multiple Myeloma life expectancy source - Arcellx July 2022 investor presentation... (full text)",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c3014c97-c9ef-4804-9560-765298dab277",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.45,
        "x": 0.53,
        "y": 0.75
      },
      "kind": "table",
      "text": "Comparison of NXC-201 vs Allogeneic BCMA-CAR-T vs BCMA bispecific engagers on ORR and CR/sCR metrics.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3b3db7dc-43ad-4f08-a2b4-ed8a1edeabfc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.45,
        "x": 0.02,
        "y": 0.2
      },
      "kind": "title",
      "text": "Market Size",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "609c4778-8347-4fee-bf08-c3d82d9327be",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.45,
        "x": 0.53,
        "y": 0.2
      },
      "kind": "title",
      "text": "Why Now",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6badeef0-670f-44f8-a4f3-844aaa86a12e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.02,
        "y": 0.05
      },
      "kind": "title",
      "text": "NXC-201 Entering Large Markets At a Pivotal Moment",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "df0dc53b-9be4-438c-b8c4-e1f16e608ba0",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Market Segmentation Pyramid",
      "slug": "market-segmentation-pyramid",
      "agent": null,
      "layer": "slide",
      "matchId": "3649cf6e-f702-41e8-936c-d0768efa3558",
      "evidence": "Hematologic cancers market opportunity",
      "confidence": 0.5
    }
  ],
  "frameworks": [
    {
      "name": "market-sizing",
      "slug": null,
      "matchId": "276f4a60-ccf6-445c-93ec-7474b9852530",
      "evidence": "Quantification of total addressable market growth from $60B to $120B.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 36,
      "from": 19,
      "beatId": "ab2925a6-fd2e-488b-b430-e58988921ddc",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Evidence & Proof",
      "beatSlug": "consultants-gambit-evidence-proof",
      "evidence": "Slides 19-36 provide clinical data and results for NXC-201",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 32,
      "from": 30,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "97496501-8d4d-4cba-92cc-0cef806b4d26",
      "evidence": "Slides 30-32 discuss the market opportunity for NXC-201",
      "position": 2,
      "objective": "What is the potential for NXC-201 in large markets?",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.6,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}